Short Interest in Intelligent Bio Solutions Inc. (NASDAQ:INBS) Increases By 13.9%

Intelligent Bio Solutions Inc. (NASDAQ:INBS) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 420,600 shares, a growth of 13.9% from the October 15th total of 369,400 shares. Currently, 9.8% of the company’s stock are short sold. Based on an average daily trading volume, of 1,740,000 shares, the days-to-cover ratio is presently 0.2 days.

Intelligent Bio Solutions Trading Down 0.7 %

Shares of INBS opened at $1.47 on Monday. The stock has a 50-day simple moving average of $1.68 and a 200-day simple moving average of $1.75. Intelligent Bio Solutions has a 1 year low of $1.00 and a 1 year high of $11.70.

Intelligent Bio Solutions (NASDAQ:INBS) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.17). The company had revenue of $872.29 million during the quarter. Intelligent Bio Solutions had a negative net margin of 1.19% and a negative return on equity of 147.50%. As a group, equities analysts predict that Intelligent Bio Solutions will post -1.25 earnings per share for the current year.

Institutional Investors Weigh In On Intelligent Bio Solutions

An institutional investor recently bought a new position in Intelligent Bio Solutions stock. Virtu Financial LLC bought a new position in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,537 shares of the company’s stock, valued at approximately $53,000. Virtu Financial LLC owned approximately 0.40% of Intelligent Bio Solutions as of its most recent filing with the SEC. Hedge funds and other institutional investors own 32.97% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.